Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Adma Biologics (ADMA) Cost of Revenue (2016 - 2025)

Adma Biologics' Cost of Revenue history spans 13 years, with the latest figure at -$162.2 million for Q4 2025.

  • For Q4 2025, Cost of Revenue fell 179.55% year-over-year to -$162.2 million; the TTM value through Dec 2025 reached -$104.9 million, down 142.19%, while the annual FY2025 figure was $4.8 million, 97.66% down from the prior year.
  • Cost of Revenue reached -$162.2 million in Q4 2025 per ADMA's latest filing, down from $1.3 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $203.9 million in Q4 2024 to a low of -$162.2 million in Q4 2025.
  • Average Cost of Revenue over 5 years is $25.0 million, with a median of $4.0 million recorded in 2021.
  • The largest YoY upside for Cost of Revenue was 5712.85% in 2025 against a maximum downside of 179.55% in 2025.
  • A 5-year view of Cost of Revenue shows it stood at $71.6 million in 2021, then plummeted by 49.98% to $35.8 million in 2022, then skyrocketed by 362.76% to $165.7 million in 2023, then rose by 23.08% to $203.9 million in 2024, then tumbled by 179.55% to -$162.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Cost of Revenue are -$162.2 million (Q4 2025), $1.3 million (Q3 2025), and $54.8 million (Q2 2025).